Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Alatri, A, Armstrong, A-E, Greinacher, A, Koster, A, Kozek-Langenecker, SA, Lancé, MD, Link, A, Nielsen, JD, Sandset, PM, Spanjersberg, AJ & Spannagl, M 2012, 'Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective' Thrombosis Research, bind 129, nr. 4, s. 426-33. https://doi.org/10.1016/j.thromres.2011.11.041

APA

CBE

MLA

Vancouver

Author

Alatri, Adriano ; Armstrong, Anna-Elina ; Greinacher, Andreas ; Koster, Andreas ; Kozek-Langenecker, Sibylle A ; Lancé, Marcus D ; Link, Andreas ; Nielsen, Jørn D ; Sandset, Per M ; Spanjersberg, Alexander J ; Spannagl, Michael. / Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. I: Thrombosis Research. 2012 ; Bind 129, Nr. 4. s. 426-33.

Bibtex

@article{3731385f480c4c8fa905d701d1cc40c1,
title = "Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective",
abstract = "Argatroban has been introduced as an alternative parenteral anticoagulant for HIT-patients in several European countries in 2005. In 2009 a panel of experts discussed their clinical experience with argatroban balancing risks and benefits of argatroban treatment in managing the highly procoagulant status of HIT-patients. This article summarizes the main conclusions of this round table discussion. An ongoing issue is the appropriate dosing of argatroban in special patient groups. Therefore, dosing recommendations for different HIT-patient groups (ICU patients; non-ICU patients, paediatric patients, and for patients undergoing renal replacement therapies) are summarized in this consensus statement. Because of the strong correlation between argatroban dosing requirements and scores used to characterize the severity of illness (APACHE; SAPS, SOFA) suitable dosing nomograms are given. This consensus statement contributes to clinically relevant information on the appropriate use and monitoring of argatroban based on the current literature, and provides additional information from clinical experience. As the two other approved drugs for HIT, danaparoid and lepirudin are either currently not available due to manufacturing problems (danaparoid) or will be withdrawn from the market in 2012 (lepirudin), this report should guide physicians who have limited experience with argatroban how to use this drug safely in patients with HIT.",
keywords = "Anticoagulants, Antithrombins, Dose-Response Relationship, Drug, Europe, Hematology, Heparin, Humans, Pipecolic Acids, Practice Guidelines as Topic, Thrombocytopenia, Treatment Outcome",
author = "Adriano Alatri and Anna-Elina Armstrong and Andreas Greinacher and Andreas Koster and Kozek-Langenecker, {Sibylle A} and Lanc{\'e}, {Marcus D} and Andreas Link and Nielsen, {J{\o}rn D} and Sandset, {Per M} and Spanjersberg, {Alexander J} and Michael Spannagl",
note = "Copyright {\circledC} 2011 Elsevier Ltd. All rights reserved.",
year = "2012",
doi = "10.1016/j.thromres.2011.11.041",
language = "English",
volume = "129",
pages = "426--33",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Pergamon",
number = "4",

}

RIS

TY - JOUR

T1 - Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective

AU - Alatri, Adriano

AU - Armstrong, Anna-Elina

AU - Greinacher, Andreas

AU - Koster, Andreas

AU - Kozek-Langenecker, Sibylle A

AU - Lancé, Marcus D

AU - Link, Andreas

AU - Nielsen, Jørn D

AU - Sandset, Per M

AU - Spanjersberg, Alexander J

AU - Spannagl, Michael

N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.

PY - 2012

Y1 - 2012

N2 - Argatroban has been introduced as an alternative parenteral anticoagulant for HIT-patients in several European countries in 2005. In 2009 a panel of experts discussed their clinical experience with argatroban balancing risks and benefits of argatroban treatment in managing the highly procoagulant status of HIT-patients. This article summarizes the main conclusions of this round table discussion. An ongoing issue is the appropriate dosing of argatroban in special patient groups. Therefore, dosing recommendations for different HIT-patient groups (ICU patients; non-ICU patients, paediatric patients, and for patients undergoing renal replacement therapies) are summarized in this consensus statement. Because of the strong correlation between argatroban dosing requirements and scores used to characterize the severity of illness (APACHE; SAPS, SOFA) suitable dosing nomograms are given. This consensus statement contributes to clinically relevant information on the appropriate use and monitoring of argatroban based on the current literature, and provides additional information from clinical experience. As the two other approved drugs for HIT, danaparoid and lepirudin are either currently not available due to manufacturing problems (danaparoid) or will be withdrawn from the market in 2012 (lepirudin), this report should guide physicians who have limited experience with argatroban how to use this drug safely in patients with HIT.

AB - Argatroban has been introduced as an alternative parenteral anticoagulant for HIT-patients in several European countries in 2005. In 2009 a panel of experts discussed their clinical experience with argatroban balancing risks and benefits of argatroban treatment in managing the highly procoagulant status of HIT-patients. This article summarizes the main conclusions of this round table discussion. An ongoing issue is the appropriate dosing of argatroban in special patient groups. Therefore, dosing recommendations for different HIT-patient groups (ICU patients; non-ICU patients, paediatric patients, and for patients undergoing renal replacement therapies) are summarized in this consensus statement. Because of the strong correlation between argatroban dosing requirements and scores used to characterize the severity of illness (APACHE; SAPS, SOFA) suitable dosing nomograms are given. This consensus statement contributes to clinically relevant information on the appropriate use and monitoring of argatroban based on the current literature, and provides additional information from clinical experience. As the two other approved drugs for HIT, danaparoid and lepirudin are either currently not available due to manufacturing problems (danaparoid) or will be withdrawn from the market in 2012 (lepirudin), this report should guide physicians who have limited experience with argatroban how to use this drug safely in patients with HIT.

KW - Anticoagulants

KW - Antithrombins

KW - Dose-Response Relationship, Drug

KW - Europe

KW - Hematology

KW - Heparin

KW - Humans

KW - Pipecolic Acids

KW - Practice Guidelines as Topic

KW - Thrombocytopenia

KW - Treatment Outcome

U2 - 10.1016/j.thromres.2011.11.041

DO - 10.1016/j.thromres.2011.11.041

M3 - Journal article

VL - 129

SP - 426

EP - 433

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 4

ER -

ID: 36764745